Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. - Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA Jr; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; et al. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999)